18 completed, 2 not yet recruiting, 2 terminated, 2 unknown. 16 Phase 2, 10 Phase 3, 3 Phase 1, 1 Not applicable.
Follow Placebo Ophthalmic Solution: new trials by email Literature Review of Placebo Ophthalmic Solution trials Research Report on Placebo Ophthalmic Solution
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study of RCI001 Ophthalmic Solution in Participants With Dry Eye Disease RCI001 Ophthalmic Solution, Placebo Ophthalmic Solution - Dry Eye | Phase 2 | Not yet recruiting | Rudacure | 200 | 2027-09-01 | 2026-06-04 |
| Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus GLK-221 Ophthalmic Solution, Placebo Ophthalmic Solution - Keratoconus | Phase 2 | Recruiting | Glaukos Corporation | 100 | 2025-12-23 | 2026-02-10 |
| Efficacy of Topical Atropine Eye Drops for Control of Myopia Progression Among Children Attending Mansoura University Ophthalmic Center Atropine 0.05% Eye drops, Placebo ophthalmic solution - Myopia | Phase 2 / Phase 3 | Not yet recruiting | Mansoura University | 45 | 2025-09-01 | 2025-09-09 |
| A Study of Efficacy and Safety of PHP-201 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Placebo ophthalmic solution, PHP-201 ophthalmic solution - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Unknown | pH Pharma | 110 | 2021-11-01 | 2021-06-18 |
| Study of ST-100 as Treatment for Dry Eye Disease ST-100 Ophthalmic Solution, Placebo Ophthalmic Solution - Dry Eye Disease | Phase 2 | Completed | Stuart Therapeutics, Inc. | 160 | 2021-05-17 | 2024-03-13 |
| Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye PL9643 Ophthalmic Solution, Placebo Ophthalmic Solution - Dry Eye Disease | Phase 2 | Completed | ORA, Inc. | 160 | 2020-02-14 | 2020-11-13 |
| Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression Atropine 0.1% Ophthalmic Solution, Atropine 0.01% Ophthalmic Solution, Placebo Ophthalmic Solution - Myopia | Phase 3 | Terminated | Eyenovia Inc. | 438 | 2019-06-03 | 2025-01-06 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution AKB-9778 Ophthalmic Solution, Placebo Ophthalmic Solution - Ocular Hypertension, Primary Open Angle Glaucoma | Phase 1 | Completed | Aerpio Therapeutics | 91 | 2019-05-02 | 2020-02-25 |
| A Study Assessing the Efficacy and Safety of DE-127 Ophthalmic Solution in Subjects With Mild or Moderate Myopia (APPLE) DE-127 Ophthalmic Solution low dose, DE-127 Ophthalmic Solution medium dose, DE-127 Ophthalmic Solution high dose - Myopia | Phase 2 | Completed | Santen Pharmaceutical Co., Ltd. | 99 | 2017-10-27 | 2020-08-26 |
| CoQun Study - (COQUN): a Study to Evaluate the Effects of CoQun in Patients Affected by Open-angle Glaucoma Coqun® ophthalmic solution, Placebo ophthalmic solution - Open Angle Glaucoma | Not applicable | Terminated | Mario Negri Institute for Pharmacological Research | 111 | 2017-09-04 | 2024-03-13 |
| Evaluation of PHP-201 Ophthalmic Solution in Patients With Normal Tension Glaucoma PHP-201 0.25% ophthalmic solution, PHP-201 0.5% ophthalmic solution, Placebo ophthalmic solution - Normal Tension Glaucoma | Phase 2 | Completed | pH Pharma | 119 | 2017-03-06 | 2018-10-26 |
| A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of HL217 Eye Drop in Healthy Male Subjects Cohort 1: HL217 Ophathalmic Solution QD, Cohort 2: HL217 Ophathalmic Solution BID, Cohort 3: HL217 Ophthalmic Solution QID - Healthy Subject | Phase 1 | Completed | Hanlim Pharm. Co., Ltd. | 24 | 2016-08-01 | 2019-04-01 |
| Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD Squalamine lactate ophthalmic solution, 0.2%, Placebo Ophthalmic solution, ranibizumab - Age-related Macular Degeneration | Phase 3 | Unknown | Ohr Pharmaceutical Inc. | 230 | 2016-04-12 | 2017-04-27 |
| A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease 1% Tavilermide Ophthalmic Solution, Placebo Ophthalmic Solution - Keratoconjunctivitis Sicca | Phase 3 | Completed | Mimetogen Pharmaceuticals USA, Inc. | 400 | 2016-01-01 | 2019-08-16 |
| A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study- Placebo ophthalmic solution, DE-117 ophthalmic solution low, DE-117 ophthalmic solution high - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 2 / Phase 3 | Completed | Santen Pharmaceutical Co., Ltd. | 253 | 2015-12-06 | 2017-11-20 |
| A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye 1% Tavilermide Ophthalmic Solution, Placebo Ophthalmic Solution - Keratoconjunctivitis Sicca | Phase 3 | Completed | Mimetogen Pharmaceuticals USA, Inc. | 429 | 2015-12-01 | 2019-08-16 |
| A Study to Evaluate the Safety and Efficacy of EV06 Ophthalmic Solution in Improving Vision in Subjects With Presbyopia EV06 Ophthalmic Solution, Placebo Ophthalmic Solution - Presbyopia | Phase 1 / Phase 2 | Completed | Encore Vision, Inc. | 75 | 2015-09-16 | 2018-07-02 |
| Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration Squalamine Lactate Ophthalmic Solution, 0.2%, Placebo Ophthalmic Solution, ranibizumab - Age-Related Macular Degeneration | Phase 2 | Withdrawn | Ohr Pharmaceutical Inc. | 2015-07-01 | 2017-04-27 | |
| Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye cis-UCA ophthalmic solution 1.0%, cis-UCA ophthalmic solution 2.5%, Placebo ophthalmic solution - Dry Eye Syndrome | Phase 2 | Completed | Herantis Pharma Plc. | 161 | 2014-12-01 | 2015-09-09 |
| Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, Placebo Ophthalmic Solution - Chronic Graft-versus-host Disease | Phase 2 | Completed | Rigel Pharmaceuticals | 35 | 2014-03-01 | 2016-10-10 |
Showing 20 of 27. Sign in to see all of them.
Dry Eye Syndromes (9) · Glaucoma, Open-Angle (5) · Ocular Hypertension (4) · Keratoconjunctivitis Sicca (3) · Myopia (3) · Conjunctivitis, Allergic (2) · Macular Degeneration (2) · Bronchiolitis Obliterans Syndrome (1) · Choroidal Neovascularization (1) · Glaucoma (1) · Keratoconus (1) · Low Tension Glaucoma (1) · Presbyopia (1)
Santen Pharmaceutical Co., Ltd. (6) · Mimetogen Pharmaceuticals USA, Inc. (4) · Ohr Pharmaceutical Inc. (2) · pH Pharma (2) · Aerpio Therapeutics (1) · Encore Vision, Inc. (1) · Eyenovia Inc. (1) · Glaukos Corporation (1) · Hanlim Pharm. Co., Ltd. (1) · Herantis Pharma Plc. (1) · Laboratorios Sophia S.A de C.V. (1) · Mansoura University (1) · Mario Negri Institute for Pharmacological Research (1) · ORA, Inc. (1) · Rigel Pharmaceuticals (1)
United States (14) · Japan (5) · South Korea (2) · Italy (1) · Mexico (1) · Singapore (1)
Garth Cumberlidge, PhD (3) · Avner Ingerman, MD (2) · David Bell (1) · Gail Torkildsen, MD (1) · John Lonsdale, MD (1) · Luciano Quaranta, MD PhD (1) · Miriam Becerra-Cotta, MD (1) · Robert O Baratta, MD (1)
PMID 25163405, PMID 28736340, PMID 31301054, PMID 32533949, PMID 37677000